Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death

BACKGROUND In patients with hepatitis C virus (HCV) infection and cirrhosis, long term outcome and the incidence of hepatocellular carcinoma (HCC) are still debated. DESIGN From January 1987 to January 1997, 416 patients (240 male, median age 57 years) with uncomplicated Child-Pugh A HCV related cirrhosis were followed in two Paris area centres from diagnosis of cirrhosis until death or reference date (1 June 1998). The analysis used a three state disability model generalising the Cox model. RESULTS Of the 416 patients, 60 developed HCC with a five year rate of 13.4% (95% confidence interval (CI) 9.0-17.8%) and 83 died (including 34 with HCC), with a five year death rate of 15.3% (95% CI 12.6-18.0%). By multivariable analysis, time to HCC relied on age (hazard ratio (HR) 1.05 per year; p=0.0005), male sex (HR 2.13; p=0.01), oesophageal varices (HR 2.36; p= 0.008), decreased platelet count (HR 0.99; p=0. 03), and bilirubin level (HR 1.01; p=0.003), while death after HCC was mainly related to tobacco consumption (HR 1.04; p=0.0006). In contrast, death free of HCC was dependent on age (HR 1.04; p=0.01), oesophageal varices (HR 2.75; p=0.001), low platelet count (HR 0.99; p=0.006), and albumin level (HR 0.90; p=0.0001). CONCLUSION The incidence of HCC and mortality should be higher in these patients than previously stated, and prognostic factors of HCC and death are closely related age and symptoms of portal hypertension.

[1]  H. Thomas,et al.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C , 1997 .

[2]  H. Tsukuma,et al.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease. , 1993, The New England journal of medicine.

[3]  M. Rapicetta,et al.  Hepatitis C Virus Infection as a Risk Factor for Hepatocellular Carcinoma in Patients with Cirrhosis , 1992, Annals of Internal Medicine.

[4]  A. Pezzoli,et al.  Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. , 1996, Journal of hepatology.

[5]  S. Seki,et al.  Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis , 1995, The Lancet.

[6]  Richard E. Sampliner,et al.  The Natural History of Community-Acquired Hepatitis C in the United States , 1993 .

[7]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[8]  N. Terrault,et al.  Hepatitis C Virus in the Setting of Transplantation , 1995, Seminars in liver disease.

[9]  M. Tong,et al.  Clinical outcomes after transfusion-associated hepatitis C. , 1995, The New England journal of medicine.

[10]  M. Roncalli,et al.  Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. , 1995, Gastroenterology.

[11]  W. Caselmann,et al.  Hepatitis C virus infection as a major risk factor for hepatocellular carcinoma. , 1996, Journal of hepatology.

[12]  M. Mondelli,et al.  Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study , 1997, Hepatology.

[13]  L. Benvegnu' Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. , 1998, Lancet.

[14]  P. Marcellin,et al.  Treatment of hepatitis C virus–related cirrhosis: A randomized, controlled trial of interferon alfa‐2b versus no treatment , 1999, Hepatology.

[15]  R. Koretz,et al.  Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second Decade , 1993, Annals of Internal Medicine.

[16]  K. Ishak,et al.  Long‐term clinical and histopathological follow‐up of chronic posttransfusion hepatitis , 1991, Hepatology.

[17]  P. Andersen,et al.  Multistate models in survival analysis: a study of nephropathy and mortality in diabetes. , 1988, Statistics in medicine.

[18]  Roger Williams,et al.  Hepatitis C virus infection in the development of hepatocellular carcinoma in cirrhosis. , 1997, Journal of hepatology.

[19]  C. Keirns,et al.  Hepatitis C: a disease with a wide morphological spectrum? , 1996, Journal of clinical gastroenterology.

[20]  R. Purcell,et al.  NON-A, NON-B POST-TRANSFUSION HEPATITIS , 1977, The Lancet.

[21]  A. Bhalla,et al.  Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. , 1997, Gastroenterology.

[22]  Ørnulf Borgan,et al.  Counting process models for life history data: a review , 1984 .

[23]  R. Purcell,et al.  Interrelationship of blood transfusion, non‐A, non‐B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus , 1990, Hepatology.

[24]  K. Chayama,et al.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: A prospective observation of 795 patients with viral and alcoholic cirrhosis , 1993, Hepatology.

[25]  Y. Ohashi,et al.  Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA , 1999, Hepatology.

[26]  G Realdi,et al.  Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). , 1997, Journal of hepatology.

[27]  C. Chastang,et al.  Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis , 1996, Hepatology.

[28]  F. Iber,et al.  Long-Term Mortality after Transfusion-Associated Non-A, Non-B Hepatitis , 1992 .

[29]  O. Yokosuka,et al.  Incidence of hepatocellular carcinoma in chronic hepatitis B and C: A prospective study of 251 patients , 1995, Hepatology.

[30]  J. Pawlotsky,et al.  Epidemiological factors affecting the severity of hepatitis C virus‐related liver disease: A French survey of 6,664 patients , 1997, Hepatology.

[31]  O. Chazouilleres,et al.  Determinants of outcome of compensated hepatitis C virus‐related cirrhosis , 1998, Hepatology.

[32]  N. Hayashi,et al.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C , 1998, Hepatology.

[33]  Y. Imai,et al.  Relation of Interferon Therapy and Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 1998, Annals of Internal Medicine.